Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes
Drug Metabolism and Disposition · 2024
DOI: 10.1124/dmd.124.001693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2024. Verfasst von Lloyd Wei Tat Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut lloydweitat.tang@pfizer.com. Hauptthemen laut MEDLINE: Aldehyde Oxidase, Hepatocytes, Phenotype, Quinazolines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut lloydweitat.tang@pfizer.com.
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut.
ORCID-Profile: Lloyd Wei Tat Tang, Kimberly Lapham
Zitieren
APA
Tang, L. W. T., DaSilva, E., Lapham, K., & Obach, R. S. (2024). Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.124.001693
Vancouver
Tang LWT, DaSilva E, Lapham K, Obach RS. Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes. Drug Metabolism and Disposition. 2024. doi:10.1124/dmd.124.001693
BibTeX
@article{Tang2024,
author = {Tang, Lloyd Wei Tat and DaSilva, Ethan and Lapham, Kimberly and Obach, R Scott},
title = {Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes},
journal = {Drug Metabolism and Disposition},
year = {2024},
doi = {10.1124/dmd.124.001693}
}
EUVIMED